Molecular and cellular basis of genetically inherited skeletal muscle disorders

被引:0
作者
James J. Dowling
Conrad C. Weihl
Melissa J. Spencer
机构
[1] University of Toronto,Departments of Paediatrics and Molecular Genetics
[2] The Hospital for Sick Children Peter Gilgan Centre for Research and Learning (PGCRL),Division of Neurology and Program for Genetics and Genome Biology
[3] Washington University School of Medicine,Department of Neurology
[4] David Geffen School of Medicine at UCLA,Department of Neurology
来源
Nature Reviews Molecular Cell Biology | 2021年 / 22卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Neuromuscular disorders comprise a diverse group of human inborn diseases that arise from defects in the structure and/or function of the muscle tissue — encompassing the muscle cells (myofibres) themselves and their extracellular matrix — or muscle fibre innervation. Since the identification in 1987 of the first genetic lesion associated with a neuromuscular disorder — mutations in dystrophin as an underlying cause of Duchenne muscular dystrophy — the field has made tremendous progress in understanding the genetic basis of these diseases, with pathogenic variants in more than 500 genes now identified as underlying causes of neuromuscular disorders. The subset of neuromuscular disorders that affect skeletal muscle are referred to as myopathies or muscular dystrophies, and are due to variants in genes encoding muscle proteins. Many of these proteins provide structural stability to the myofibres or function in regulating sarcolemmal integrity, whereas others are involved in protein turnover, intracellular trafficking, calcium handling and electrical excitability — processes that ensure myofibre resistance to stress and their primary activity in muscle contraction. In this Review, we discuss how defects in muscle proteins give rise to muscle dysfunction, and ultimately to disease, with a focus on pathologies that are most common, best understood and that provide the most insight into muscle biology.
引用
收藏
页码:713 / 732
页数:19
相关论文
共 484 条
[1]  
Engel AG(2015)Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment Lancet Neurol. 14 420-434
[2]  
Shen XM(1986)Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene Nature 323 646-650
[3]  
Selcen D(1987)Localization and cloning of Xp21 deletion breakpoints involved in muscular dystrophy Hum. Genet. 75 221-227
[4]  
Sine SM(1987)Dystrophin: the protein product of the Duchenne muscular dystrophy locus Cell 51 919-928
[5]  
Monaco AP(2020)Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies Fac. Rev. 9 12-140
[6]  
Monaco AP(2017)Myotonic dystrophy: approach to therapy Curr. Opin. Genet. Dev. 44 135-306
[7]  
Bertelson CJ(2020)Meeting report: the 2020 FSHD International Research Congress Skelet. Muscle 10 295-262
[8]  
Colletti-Feener C(2015)Emerging preclinical animal models for FSHD Trends Mol. Med. 21 259-319
[9]  
Kunkel LM(1989)Association of dystrophin and an integral membrane glycoprotein Nature 338 315-31224
[10]  
Hoffman EP(1990)Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle Nature 345 31221-165